Investigating genetic mutations in uterine fibroids for new treatments
Official title: Understanding the functional role of fibroid subtype mutations for drug discovery
Funded at Henry Ford Health + Michigan State University Health Sciences · NIH-10886903 · Data updated 2026-11-12
This study is looking at how certain gene changes might cause uterine fibroids, which are non-cancerous growths that many women experience, to help find better treatments tailored for those affected.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry Ford Health + Michigan State University Health Sciences NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $107,860 |
| NIH project number | 1K99HD112539-01A1 |
| Project ID | NIH-10886903 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women of reproductive age who are experiencing symptoms related to uterine fibroids.
✕Less likely to help
Patients who do not have uterine fibroids or are not experiencing related symptoms may not benefit from this research.
What this research studies
This research focuses on understanding how specific genetic mutations contribute to the development of uterine fibroids, which are common benign tumors in women. By examining the roles of two key mutations, HMGA2 and MED12, in human myometrial cells, the research aims to uncover how these mutations lead to fibroid formation. The approach involves manipulating these genes to observe their effects on cell behavior, which could inform the development of targeted therapies. This work is essential for advancing personalized medicine for women affected by fibroids.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and personalized treatments for uterine fibroids.
How similar studies have gone: Previous research has shown promise in understanding genetic mutations in tumors, suggesting that this approach could yield valuable insights for fibroid treatment.
Where this research is happening
-
Henry Ford Health + Michigan State University Health Sciences
East Lansing, United States Active
Researchers
- Principal investigator: Paul, Emmanuel — Henry Ford Health + Michigan State University Health Sciences
- Study coordinator: Paul, Emmanuel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.